Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

Inclusion Criteria: * Aged 18 years or more * A diagnosis of ocular hypertension or open-angle glaucoma and prior use of timolol or prostaglandin. * Meet specific IOP level at visit 1 (screening), visit 2 (run-in) and visit 3 (baseline). * Meet specific visual acuity score * Are willing to follow instructions * Have provided a written informed consent Exclusion Criteria: * Females who are pregnant, nursing or planning pregnancy * IOP of 35 mmHg or greater * Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye * Suspected contraindication or hypersensitivity to study medications tafluprost or timolol (e.g. asthma, low pulse)or to wash-out medication brinzolamide * Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening * Use of contact lenses at Screening or during the study * Presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters * Current participation in another clinical trial within the last 30 days